SANTA FE, N.M., Oct. 2 /PRNewswire-FirstCall/ -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature's Interim Tobacco Settlement Committee in support of the lawmakers' $1.3 million proposal for funding a clinical study using the company's assay for early lung cancer detection.
The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state's 30-day legislative session beginning January 15, 2008.
"Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives," said Cousins. "We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that."
Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda's efforts. "We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives."
Biomoda's technology is based on a patented porphyrin application that
preferentially binds to cancerous or aberrant cells extracted from lung
sputum samples. Cancerous cells glow red under fluorescent light to allow
detection under a microscope. The patented technology, a non-invasive
|SOURCE Biomoda, Inc.|
Copyright©2007 PR Newswire.
All rights reserved